Blackstone places $400M bet to launch Ferring gene therapy subsidiary

Ferring created a subsidiary to house registration-stage bladder cancer gene therapy nadofaragene firadenovec and drew a $400 million investment from Blackstone on Monday.

Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched FerGene to commercialize nadofaragene in the U.S. and further its global development. Ferring will also invest up to $170 million in the subsidiary. ...